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Abstract
Objective—Plasma adiponectin is strongly associated with various components of metabolic
syndrome, type 2 diabetes and cardiovascular outcomes. Concentrations are highly heritable and
differ between men and women. We therefore aimed to investigate the genetics of plasma adiponectin
in men and women.
Methods—We combined genome-wide association scans of three population-based studies
including 4659 persons. For the replication stage in 13795 subjects, we selected the 20 top signals
of the combined analysis, as well as the 10 top signals with p-values less than 1.0*10-4 for each the
men- and the women-specific analyses. We further selected 73 SNPs that were consistently associated
with metabolic syndrome parameters in previous genome-wide association studies to check for their
association with plasma adiponectin.
Results—The ADIPOQ locus showed genome-wide significant p-values in the combined
(p=4.3*10-24) as well as in both women- and men-specific analyses (p=8.7*10-17 and p=2.5*10-11,
respectively). None of the other 39 top signal SNPs showed evidence for association in the replication
analysis. None of 73 SNPs from metabolic syndrome loci exhibited association with plasma
adiponectin (p>0.01).
Conclusions—We demonstrated the ADIPOQ gene as the only major gene for plasma adiponectin,
which explains 6.7% of the phenotypic variance. We further found that neither this gene nor any of
the metabolic syndrome loci explained the sex differences observed for plasma adiponectin. Larger
studies are needed to identify more moderate genetic determinants of plasma adiponectin.
Keywords
adiponectin; genome-wide association study; polymorphism; cardiovascular disease; metabolic
syndrome
Introduction
Plasma adiponectin is a quantitative parameter, which has a strong role in modulating insulin
sensitivity and glucose homeostasis. It has been found to be decreased in humans with type 2
diabetes and cardiovascular disease (CVD) (1,2) and decreased plasma adiponectin was found
to be associated with deteriorated levels of virtually all parameters of the metabolic syndrome
(3-5). Experiments in mice transgenic or deficient for the adiponectin gene have underscored
the functional role of adiponectin on various components of the metabolic syndrome and
diabetes mellitus (3,6,7).
Concerning CVD outcomes the observations on adiponectin are heterogeneous as recently
reviewed extensively (8): experimental data demonstrate that adiponectin stimulates the
production of nitric oxide, positively affects inflammatory mechanisms, has anti-apoptotic
properties and is involved in vascular remodeling. Clinical data are diverse depending mainly
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on the disease stage when investigated. Low levels seem to be associated with worse outcomes
when measured in healthy conditions. However, there is accumulating data that in diseased
states such as chronic heart failure or existing CVD high rather than low levels predict CVD
and non-CVD mortality. Knowing the genes which affect plasma adiponectin might be helpful
to disentangle adiponectin as cause or consequence of disease states using a Mendelian
randomization approach (9).
Plasma adiponectin shows pronounced differences between men and women with about 1.5
times higher concentrations in women (10). An explanation for these differences is lacking as
plasma adiponectin is only moderately influenced by nutritional behavior, physical activity or
other environmental components (5,8,11). However, there is clear evidence for a high
heritability of about 50% (4,12-14) which one study even suggested to be sex-dependent
(14). In line with lower plasma adiponectin in men, higher prevalences of type 2 diabetes and
impaired fasting glucose were also reported in men (15).
Recent genome-wide association (GWA) scans have highlighted the potential of genetic factors
with differential sex effects on concentrations of uric acid (16-18) and lipids (19), waist
circumference (20) or schizophrenia (21). Many of these phenotypes show pronounced sex-
specific differences in plasma concentrations or prevalence. A sex-differential SNP association
with a quantitative phenotype can even mask a real association if data are analyzed without
stratification. One example is a SNP near the LYPLAL1 gene which recently showed a strong
association with waist-hip-ratio in women but not in men and would have been missed in the
sex-combined analysis (20). To our knowledge, sex-specific differences for genetic effects on
plasma adiponectin have not been investigated so far.
In the study at hand, we aimed to identify not only novel genes modulating plasma adiponectin
but also whether genetic effects are differential between men and women. We combined this
meta-analysis with a candidate gene approach considering all genes which have recently been
associated with singular components of the metabolic syndrome in GWA studies.
Methods
Study cohorts and Genotyping
Our gene discovery included 4659 subjects (women=2562, men=2097) derived from three
population-based studies, the Erasmus Rucphen Family Study (ERF, n=1820) (22), the follow-
up of the third survey from the “Kooperative Gesundheitsforschung in der Region Augsburg”
Study (KORA-F3, n=1644) (23), and the MICROS Study (n=1195) (24). The replication
contained 13795 subjects (women=7673, men=6122 from the study cohorts CoLaus (n=5381),
Framingham (n=2228), GEMS (n=1780), ALSPAC (n=1415), TWINS UK (n=1399),
InChianti (n=1027) and BLSA (n=565).
All studies had genotypes available from genome-wide SNPs imputed based on the HapMap
Ceu r22 reference sample after quality control. Measurement of adiponectin was made by
ELISAs (from Mercodia, BioVendor and R&D Systems) or RIA (Linco). Details on study
cohorts including the phenotyping for adiponectin measurements, genotyping methods,
statistical analysis, and descriptive statistics are provided in the Supplementary Material and
Supplementary Table S1.
Study design and statistical analysis
The study design is summarized in Figure 1.
GWA analyses (stage 1)—GWA analyses were conducted using a standardized protocol
in each of the three stage 1 studies. For each of the 2,585,854 SNPs, linear regression using an
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additive genetic model was performed for log-transformed adiponectin values adjusting for
age, sex, and BMI and accounting for the uncertainty in the inferred genotype from the
imputation by utilizing the estimated genotype probabilities (implemented in MACH2QTL
and GenABEL/ProABEL, respectively). All analyses were repeated for men and women
separately. Relatedness between study participants was accounted for where appropriate (ERF,
MICROS). Genomic control was applied when appropriate with study-specific lambda factors
being 1.05, 1.05, and 0.99 for ERF, KORA, and MICROS, respectively. The beta-estimates of
the three cohorts were combined using a fixed effect model. Also, a scaling-invariant p-value
pooling meta-analysis using a weighted Z-score method was applied. For each SNP, we tested
for significant differences between pooled men-specific beta-estimates across the three GWA
studies as well as women-specific beta-estimates (see Supplementary Material for details).
GWA SNP selection—We selected three types of interesting regions to identify potentially
novel signals for plasma adiponectin: (1) from the sex-combined sample (20 loci), (2) from
the analysis in women (10 loci) and (3) in men (10 loci). Loci were considered as interesting
and one SNP per locus was selected, if the combined p-values were less than 1*10-4 and if
study-specific MAF was greater than 5% and imputation quality r2 greater than 0.2.
Replication analysis (stage 2)—For the selected 40 SNPs, we attempted replication based
on 7 studies with the same study-specific SNP analysis as for stage 1 studies. A stage 2 only
and a joint analysis of stage 1 and 2 (n=18454) was performed using the scaling-invariant
weighted Z-score method.
Further statistical issues—In stage 1, we had 92% power to detect a variant that explains
1% of the variance of plasma adiponectin with genome-wide significance (alpha=5*10-8). In
the stage 1 and stage 2 combined analysis, we had 99% power to yield genome-wide significant
evidence for the 40 selected SNPs if they explained 1% of more of the variance in plasma
adiponectin.
Candidate gene approach—From the literature, we identified loci associated with
metabolic syndrome parameters in large GWA studies to obtain a list of candidate gene SNPs
for adiponectin levels. We examined the association of these SNPs with plasma adiponectin
from our stage 1 sex-combined and sex-stratified meta-analyses. For this candidate gene
approach, we had 92% power to detect a SNP association that explains 0.5% of the variance
accounting for the 73 SNPs tested (alpha=0.0007).
Percentage of variance explained—The general population design of KORA enabled
computation of the proportion of the adiponectin variance explained by all analyzable
ADIPOQ SNPs (i.e. SNPs available in all three GWA studies in the 50kb region of the
ADIPOQ locus with MAF>5%), by an independent SNP set of these (i.e. selecting the SNP
with the lowest p-value in the meta-analysis for each bin of SNPs with pairwise r2>0.2; r2
information was taken from HapMap), or by the top SNP alone. Computations were performed
by linear regression on the standardized residuals (log of adiponectin concentrations adjusted
for age, BMI and – if appropriate – for sex) and computing the r2 measure of the model adjusting
for the SNP(s) using PROC REG by SAS.
Heritability—The family-based design of MICROS allowed us to compute heritability of
plasma adiponectin using a polygenic model for standardized residuals of plasma adiponectin
(adjusted for age and BMI - and sex if applicable). Heritability was also computed with
additional adjustment of the top ADIPOQ SNP, with the independent SNP set as described
above (see above). Computations were performed using the R library GenABEL(25).
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Bioinformatic analysis—Bioinformatic analysis for potential functional SNPs was done
in two stages, using bioinformatic tools outlined in the GenEpi Toolbox (26) (Supplementary
Material).
Results
GWA analysis (stage 1)
Figure 2 shows the p-value, ADIPOQ-region and q-q-plots from the meta-analysis results of
plasma adiponectin of the three GWA studies, ERF, KORA and MICROS cohorts. Results are
presented for the sex-combined (n=4659) analysis as well as stratified for women (n=2562)
and men (n=2097). The combined analysis yielded one genome-wide significant locus (Figure
2A), the ADIPOQ locus (p=4.3*10-24), which was consistent in women (p=8.7*10-17) and men
(p=2.5*10-11) (Figure 2B). The q-q plot did not show evidence for bias due to population
stratification in any of the analyses (Figure 2C). The top ADIPOQ SNP rs17366568 (Table 1)
exhibited low imputation quality in ERF and MICROS that was genotyped using the Illumina
platform in contrast to high imputation quality in KORA genotyped using the Affymetrix
platform. However, other SNPs in this region such as rs3774261 reached genome-wide
significance in the combined analysis (p=3.0*10-16) and had good imputation quality in all
three stage 1 samples (0.82<r2<0.97).
Replication analysis (stage 2)
Characteristics of the 40 SNPs taken forward for replication are provided in Supplementary
Table S2. From the combined, women-, and men-specific GWA-analyses (n=13795, 7673, and
6122, respectively), only the ADIPOQ SNP remained significant in the combined analyses
(Supplementary Table S3). P-values for rs17366568 were 1.09*10-41, 2.8*10-22 and
7.8*10-23 for the combined and the analysis stratified for women and men, respectively (Table
1).
Sex-specific analyses
In line with previous reports, plasma adiponectin in women was approximately 1.5 times higher
than in men in each of the three stage 1 studies (Supplementary Table S1). Heritability
computations in the family-based MICROS study showed slightly higher estimates of 65.1%
for women and 54.0% for men (Table 2).
For each SNP, we evaluated whether the sex-specific beta-estimates combined across the three
stage 1 studies were significantly different between men and women pointing towards a gender-
SNP interaction. The q-q plot for the p-values of sex differences indicated some observed sex
difference of genetic effects beyond that expected by chance (Supplementary Figure S1A), but
not due to differences in the ADIPOQ region. For none of the SNPs in the GWA studies, the
sex-specific beta-estimates were significantly different between men and women on a genome-
wide level (Supplementary Figure S1B). For the ADIPOQ top SNP rs17366568 the p-value
for sex difference was 0.62.
Association of metabolic syndrome candidate gene SNPs with adiponectin
From the literature, we identified loci associated with metabolic syndrome parameters in large
GWA studies to obtain a list of candidate gene SNPs for adiponectin levels (Figure 1). These
were partially overlapping for the various metabolic syndrome components and included 21
SNPs for HDL cholesterol, 17 for triglycerides (7 of them were also found for HDL cholesterol
and were therefore only counted once), 12 for BMI and/or waist circumference, 18 for type 2
diabetes and/or glucose levels (one of them was already mentioned for BMI and is therefore
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only counted once), and 13 for hypertension and blood pressure. Details on these SNPs are
given in Supplementary Table S4.
Only 3 out of the 73 SNPs showed p-values between 0.01 and 0.05 for example for the gender-
combined analysis (with 3.65 expected under the assumption of no association). No p-value
was below the Bonferroni-adjusted significance level of 0.007. Thus, our data indicated no
association of these metabolic syndrome parameter SNPs with plasma adiponectin.
Sensitivity analyses
Sensitivity analyses repeating all analyses without the adjustment for BMI showed the same
results regarding the ADIPOQ genome-wide significant results, the lack of sex difference, the
lack of other SNPs in the replication stage to show replication, and the lack of metabolic
syndrome SNPs to show association with plasma adiponectin.
ADIPOQ region
A closer look at the ADIPOQ region revealed that the top SNP rs17366568 was completely
independent of all other SNPs in that region. A linkage disequilibrium (LD) plot depicting D′
and r2 measures (Figure 3) revealed that for many SNPs in the ADIPOQ region the r2 was weak
even if they were located in the same LD block (as defined by D′). At least nine SNP groups
were significantly and independently associated with plasma adiponectin. The percentage of
plasma adiponectin variance explained by the top hit was 3.8% and increased to 5.9% when
including an independent SNP set (selecting the SNP with the smallest p-value in each bin of
pairwise r2<0.2) and peaked at 6.7% when including all SNPs with MAF>5% in the 50 kb
region covering the three LD blocks (Table 2).
Bioinformatic analysis revealed two main putative functional elements located in the second
and the third LD block as depicted in Figure 3. Three SNPs located immediately up-and
downstream of rs17366568 (for details see Supplementary Table S5) are predicted to affect
10, 6 or 4, respectively, transcription factor binding sites (using adipose tissue-specific
analysis). No transcription factor binding sites or splicing regulation elements were detected
for rs17366568 itself. Therefore, it is likely that rs17366568 is not the functional variant, but
relates to a functional element located in the immediate vicinity (although regulatory potential
was very low throughout the region).
Analysis of LD block 3 (encompassing exon 3 and a large intergenic region downstream of
the ADIPOQ locus) revealed three putative regulatory promoter regions located approximately
5.1 kb, 6.3 kb and 15.8 kb downstream of the ADIPOQ locus. Interestingly, especially the
proximal two regulatory regions are known to be affected by several copy number regions (see
Figure 4 and Supplementary Table S6). However, no SNP in our data set was located directly
in these CNVs, whose functional relevance may therefore require further investigation. More
generally, the whole genomic region of ADIPOQ seems to be highly affected by copy number
variations (Figure 4).
Discussion
In the meta-analysis of genome-wide SNP association with plasma adiponectin in three
population-based studies including a total of 4655 subjects, we found genome-wide significant
evidence for the association with the ADIPOQ locus, which is a known locus for plasma
adiponectin (10,27). Furthermore, we did not identify any genome-wide significant evidence
for association in any other locus when replicating the other 39 most strongly associated loci
in 13795 independent samples. Despite the clear sex difference in plasma adiponectin, there
was no sex difference observed for the ADIPOQ SNP associations. Finally, we found, despite
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the strong association between plasma adiponectin and the metabolic syndrome, no significant
association with adiponectin for any of the chosen variants within reported loci for metabolic
syndrome parameters.
Our GWA study identified only one major locus for plasma adiponectin, the ADIPOQ gene
region. The only other GWA study on adiponectin was performed in 1845 individuals of the
GEMS Study and identified also only the ADIPOQ locus with genome-wide significance
(28). The other top seven hits from that study could not be replicated in our GWA study, neither
in the combined (all p-values >0.28) nor in the sex-specific analysis (p>0.16). In our GWA
discovery stage, the power was more than 90% to detect novel loci which explain 1% of the
adiponectin variance, and, including the replication stage, over 99% to show genome-wide
significant evidence of the 40 SNPs in the 18454 subjects. Therefore, our data suggests a lack
of a major gene locus other than ADIPOQ.
ADIPOQ was studied earlier as a candidate gene and the relationship to plasma levels has long
been recognized. The SNP rs17366568 showing the strongest association in our GWA study
explained 3.8% of the variance and this number increased to 6.7% if all analyzable SNPs in
the ADIPOQ region were included into the model. This pronounced difference of the explained
variance between the two models can be explained by a large number of SNPs independently
contributing to adiponectin levels. The SNPs contributing most to the explained variance are
not only located in the three different LD blocks but also several genetic variants within each
of at least two of the three blocks contribute to the explained variance. In total, the explained
variance was very similar to the 8% reported earlier (10). Functional studies within the
promoter of the ADIPOQ gene revealed a pronounced influence of three SNPs also investigated
in our study and the corresponding haplotypes on the promoter activity which was accompanied
by changes in the DNA binding activity interfering with transcription factor bindings sites
(29). Other studies showed that histone acetylation might influence the transcriptional
regulation of the ADIPOQ gene (30) and that pioglitazone increases plasma adiponectin by
posttranscriptional regulation (31). Finally, an extensive bioinformatic analysis revealed that
the ADIPOQ region might be a highly copy number variable region. It remains to be determined
how strong the effect of these CNVs on plasma adiponectin is.
Since adiponectin has been viewed as a marker for the metabolic syndrome, we have also
studied 73 SNPs that have been associated with any of the major determinants of metabolic
syndrome in previous GWA studies. This candidate gene-based analysis did not yield any
convincing associations with plasma adiponectin. This was surprising due to the strong link
between plasma adiponectin and the metabolic syndrome or any of its components (3-5), but
in-line with previous reports on a lack of association of the ADIPOQ SNPs with metabolic
syndrome parameters (10). Whether plasma adiponectin affects metabolic syndrome
parameters or metabolic syndrome parameters modulate adiponectin is highly debated as
illustrated in Supplementary Figure S2. If the association of any of these 73 SNPs had been
very strong with adiponectin - stronger than with the metabolic syndrome parameters - this
would have pointed towards a gene locus primarily affecting plasma adiponectin and
consecutively modulating the metabolic syndrome parameters. This is not suggested by our
data (panel A of Supplementary Figure S2). Our data on these 73 metabolic syndrome SNPs
lacks association with adiponectin beyond that expected by chance. This would rather support
the idea that genetic pathways for plasma adiponectin are different from the pathways depicted
by these 73 loci (panel B), or, alternatively, that pathways depicted by these 73 loci affect
plasma adiponectin via the metabolic syndrome parameter and the lack of association was due
to loss of power for a parameter further down the road (panel C). Both ideas (panel B and C)
would point towards the hypothesis that genetically determined adiponectin does not modulate
metabolic syndrome parameters directly.
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The present data suggests that the sex differences in plasma adiponectin can not be explained
by any major gene. The GWA approach yielded no genome-wide significant difference
between men and women for any SNP, not even the ADIPOQ locus. In fact, none of the variants
studied in the replication or in our candidate gene approach based on metabolic syndrome loci
showed a significant sex difference. Therefore, the sex-difference in plasma adiponectin might
rather be explained by sex hormones (5) or sex-specific epigenetic programming that could be
transmitted to subsequent generations in a sex-specific manner leading to transgenerational
effects as recently suggested (32).
The heritability estimates of plasma adiponectin are high with roughly 50-60% (4,12-14). The
ADIPOQ locus accounts for 6.7% of the variance in our populations-based KORA Study,
which is in-line with previous reports (10). This is also in-line with 6.6% of the heritability
accounted for by this locus in our family-based MICROS Study. While the ADIPOQ locus
association with plasma adiponectin is thus among the strongest associations for quantitative
phenotypes in genetic epidemiology, it explains only a small proportion of the overall
heritability, a puzzle observed for many other phenotypes (e.g. lipids or obesity measures)
(19,20,33). Potential explanations of this gap between explained and estimated heritability are
unknown rare variants with strong effects on adiponectin (34), unknown common loci
influencing adiponectin with small effects, or deflation of association estimates due to
heterogeneity between studies, uncertainties in the genotypes from imputation or uncertainties
in the phenotype assessment. Our study suggests that these other genetic variants influencing
plasma adiponectin are variants that explain less than 1% of the phenotypic variance. To
localize these loci and to build up gene networks which identify even trans-acting quantitative
trait loci, will require substantially larger data sets in combination with gene expression
analysis.
Strengths and Limitations of the Study
A limitation of our study is the limited sample size for gene discovery for small genetic effects,
in particular when conducting stratified analyses. Furthermore, our top hit in the ADIPOQ
locus had limited imputation quality in two of the included GWA studies, which can be
explained by the fact that KORA used a different SNP-panel (Affymetrix 500K chip) for GWAs
genotyping than ERF and MICROS (Illumina HumanHap300). For most of the other SNPs
followed in replication samples, the imputation quality was quite high. The relatively low
imputation quality of our top-hit in two of the studies explains the lower (but still genome-
wide significant) p-values in these two studies compared to KORA. This is entirely in-line with
measurement error theory: a “measurement error” (like the uncertainty induced by the
imputation) that does not depend on the phenotype (as the case here assuming that genotyping
does not depend on adiponectin in the plasma) is expected to attenuate the precision of an
underlying association yielding larger p-values. Therefore, the association in ERF and
MICROS was rather underestimated than false positive. Finally, it can be considered a
limitation of most GWAS studies that gonsomes are not analyzed due to technical issues not
yet solved concerning the imputation of SNPs which, however, is a prerequisite to allow meta-
analysis of data over various genotyping platforms used.
The strong point of our study is the population-based design, in which the participants have
not been ascertained based on the presence of pathology. Hypothesizing a genetic basis of sex
differences in plasma adiponectin, a further advantage is the sex-stratified analysis since a sex-
combined analysis would otherwise mask an association. Further, the family-based MICROS
study enables us to estimate heritability.
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Conclusions
We present a genome-wide association study on adiponectin which the first time attempts to
explain adiponectin sex difference by the underlying genetics. We conclude that there is no
major gene involved in modulating plasma adiponectin other than the known ADIPOQ locus
and that there is no major gene explaining the differences of plasma adiponectin between men
and women.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Study design illustrating the genome-wide association (GWA) study approach and the
candidate gene approach.
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Figure 2.
The analyses in panel A-C are provided for the combined sex analysis as well as the analysis
stratified for women and men. A. Manhattan plots showing p-values of association of each
SNPs in the meta-analysis with plasma adiponectin levels. SNPs are plotted on the X-axis to
their position on each chromosome against association with plasma adiponectin on the Y-axis
(shown as −log10 P-value). B. Regional Manhattan plots showing significance of association
of all SNPs in the ADIPOQ region (3q27). SNPs are plotted on the X-axis to their position on
chromosome 3 against association with plasma adiponectin on the Y-axis (shown as −log10 P-
value). In each panel, the top-SNP rs17366568 is shown as red diamond. The SNPs surrounding
this top-SNP are color-coded (see inset) to reflect their LD with the top-SNP using pair-wise
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r2 values from the KORA study. Estimated recombination rates from HapMap-CEU are plotted
in blue to illustrate the local LD structure on a secondary Y-axis. Genes and their direction of
transcription are provided below the plots using data from the UCSC genome browser. C.
Quantile-quantile (QQ) plots of SNPs. Expected p-values are plotted on X-axis against the
observed p-values plotted on the Y-axis.
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Figure 3.
Linkage disequilibrium (LD) plot of SNPs in the ADIPOQ region spanning 50kb (positions
188030-188080kb). The grey shading of the diamonds represent the pair-wise D′ and the
numbers in the diamonds represent the pair-wise r2 between the two SNPs defined by the top
left and the top right sides of the diamond. The figure clearly shows that the top-hit rs17366568
is located within an own LD block and shows virtually no correlations with any other SNP in
the entire 50kb region. The columns on the right side of the Figure show i) whether a particular
SNP is genotyped by the Affymetrix 500K chip (A) or the Illumina HumanHap300 chip (I);
all other SNPs are imputed; ii) the z-scores and iii) the p-values for each SNP-adiponection
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association for the combined analysis of the cohorts ERF, KORA and MICROS; iv) SNPs that
are correlated with an r2>0.60 are grouped in groups 1-9.
Heid et al. Page 16
Atherosclerosis. Author manuscript; available in PMC 2011 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 4.
Predicted regulatory regions in the ADIPOQ downstream region and their affection by copy
number variations. Panel A: Genomatix Software Suite: Position of the regulatory promoter
regions predicted by PromoterInspector (red boxes) and their position relative the ADIPOQ
gene region (green box). Panel B: UCSC Browser: Position of the predicted regulatory regions
(red boxes) relative to known copy number variations in the ADIPOQ gene region (represented
by bold blue lines). The numbers on the left side correspond to the accession number of the
respective copy number variation in the Database of Genomic Variants.
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Table 2
Heritability and percentage of variance explained by the ADIPOQ locus SNPs
Heritability of plasma adiponectin in the family-based study MICROS and percentage of plasma adiponectin
variance (KORA) explained by the ADIPOQ locus SNPs in KORA (region on chr 3, position 188.030 –
188.080kb).
Combined Women Men
Heritability (%) in MICROS
 no SNP adjustment 59.6 65.1 54.0
 adjusted for top hit rs17366568 58.4 64.6 51.5
 adjusted for “independent ”SNPs (n=9) a 52.9 55.1 48.1
% of variance of plasma adiponectin in KORA explained by
 top hit rs17366568 3.8 5.3 2.4
 for “independent” SNPs (n=9) a 5.9 6.3 5.1
 all SNPs with MAF >5% (n=33) b 6.7 6.4 5.5
Computations were based on standardized sex-combined or sex-specific residuals of plasma adiponectin adjusted for age (and sex if applicable) and
BMI without and with additional SNP adjustment; includes only SNPs with MAF>5% available in all three studies.
a
Among the SNPS of the ADIPOQ region with MAF > 5% and available in all three GWA studies: selecting the SNP with the smallest p-value from
each bin of SNPs with pairwise r2>0.2: rs1063539, rs16861194, rs17300539, rs17366568, rs17366743, rs3774261, rs6810075, rs7615090, rs822394
b
All SNPS of the ADIPOQ region with MAF > 5% and available in all three GWA studies: rs6810075, rs10937273, rs12637534, rs1648707, rs864265,
rs822387, rs16861194, rs17300539, rs266729, rs182052, rs16861205, rs16861209, rs822391, rs16861210, rs822394, rs822396, rs12495941,
rs7649121, rs17366568, rs2241767, rs3821799, rs3774261, rs3774262, rs17366743, rs6773957, rs1063537, rs2082940, rs1063539, rs7639352,
rs6444175, rs7628649, rs17373414, rs9860747, rs1501296, rs7615090
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